Biophage Pharma highlights its strategy to address the rapidly increasing threat of MRSA infections



    Phages to replace disinfectants in the fight against deadly bacteria

    MONTREAL, Nov. 13 /CNW Telbec/ - (TSX.V: BUG) - In response to recent
investor interest in Biophage technologies and how we can address the rapidly
increasing occurrences of life threatening MRSA (Methicillin-Resistant
Staphylococcus Aureus) outbreaks in hospitals and schools across North
America, the company is very pleased to provide an update on its development
program.
    MRSA infections are increasing at an alarming pace including in the
community. The U.S. government estimates that MRSA sickens more than
90,000 people per year and is responsible for more deaths than AIDS. A recent
review (Clinical Infectious Diseases, November 1 issue) reports that the
number of infections increased over 7% each year from 1998 to 2003, while the
economic burden to hospitals increased by nearly 12% annually (from
$8.7 billion to $14.5 billion in 2003).
    Biophage, working with its partners, in particular Hôpital Sacré-Coeur de
Montréal and Hygie Canada, is currently evaluating phages against
Staphylococcus, and particularly clinically active MRSA, to create a natural
treatment to fight this harmful bacterial pathogen. These natural phages will
be firstly used in liquid or in aerosol form for the decontamination of
hospital wards and instruments. Different techniques for the production and
delivery of concentrated and purified phage preparations are under
investigation. This environmentally-friendly decontamination process will
avoid or limit the use of harsh chemicals disinfectants and promise to
revolutionize the current methods for cleaning and disinfecting hospital
environments, schools, public restrooms or any high traffic areas.
    Since the initial FDA GRAS approval of phage products in August 2006,
Biophage technologies have gained market acceptance as an environmentally
friendly and cost effective solution for bacterial decontamination. We have
the technical knowledge and capability to bring phages from research to
production: we can isolate, purify, characterize and produce commercial large
scale volumes of phages for various applications. Along with our biosensors
program (PDS(R) biosensors), we are developing an integrated solution to
combat and control bacterial contamination.
    "We are extremely excited by the market prospects for this new
environmental friendly decontamination system based on natural phages to
combat MRSA contamination in numerous environments." commented Dr. Rosemonde
Mandeville, President and CEO. "The combination of our phage treatment and
bacterial detection devices will provide an integrated way to combat bacterial
contamination allowing rapid detection and decontamination processes to avoid
outbreaks. We look forward to 2008 to push forward theses technologies and
turn them into products for a healthier world. We would like to take this
opportunity to warmly thank our investors for their continued support."

    About Biophage Pharma Inc.

    Biophage is a Canadian biotechnology company focused on the development
of innovative phage-based products and technologies for the detection,
prevention and control of bacterial infections. Biophage operates three
divisions: (1) The Therapeutics division for the prevention and control of
bacterial contaminations in the medical, veterinary and environment fields;
(2) The Biosensors division for the development and commercialization of
PDS(R) Biosensors; both the Biosensor and Therapeutics programs have been
structured to deliver an environmentally safe solution for the early detection
and rapid control of deadly microorganisms; and (3) The Immunotox Labs
division, which provides services in Immunogenicity and Immunotoxicity,
screening for Beryllium sensitization (the BeLPT test) and exclusive MELISA(R)
for the detection of sensitization to more than 200 different allergens
including metals, penicillin, gluten, pollens and more recently Lyme disease
(Boreliosis).
    (www.biophagepharma.net; www.immunotoxlabs.com)

    The TSX Venture Exchange does not accept responsibility for the adequacy
    or accuracy of this release.
    %SEDAR: 00014714EF




For further information:

For further information: Biophage Pharma Inc.: Rosemonde Mandeville,
M.B., Ch.B., PhD., President and CEO, (514) 496-1488,
rosemonde.mandeville@biophagepharma.net; Louis Guindon, Chief Financial
Officer, (514) 496-3230, louis.guindon@biophagepharma.net

Organization Profile

BIOPHAGE PHARMA, INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890